Quick Answer
Cyclerion Therapeutics, Inc. reported Total Assets of $9.99 million for the year ending 2025.
- Cyclerion Therapeutics, Inc. showed an increase of +4.3% in Total Assets from 2024 to 2025.
- This data is from Cyclerion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $9.77 million | Q2 2019: $235.50 million | Q3 2019: $209.70 million | Q1 2020: $140.03 million | Q2 2020: $128.04 million | Q3 2020: $131.40 million | Q1 2021: $99.97 million | Q2 2021: $75.73 million | Q3 2021: $67.74 million | Q1 2022: $46.53 million | Q2 2022: $35.21 million | Q3 2022: $25.05 million | Q1 2023: $11.46 million | Q2 2023: $10.10 million | Q3 2023: $15.21 million | Q1 2024: $11.36 million | Q2 2024: $10.07 million | Q3 2024: $8.90 million | Q1 2025: $9.85 million | Q2 2025: $9.37 million | Q3 2025: $10.42 million.
- Over the full 8 years of available data (2018 to 2025), Cyclerion Therapeutics, Inc.'s Total Assets has grown by 34.9%.
- Historical annual values: Fiscal year 2025: $9.99 million | Fiscal year 2024: $9.58 million | Fiscal year 2023: $13.37 million | Fiscal year 2022: $18.08 million | Fiscal year 2021: $59.33 million | Fiscal year 2020: $115.38 million | Fiscal year 2019: $186.48 million | Fiscal year 2018: $7.40 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: